Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 1018-1028

  Sayama, Hiroyuki ^a   Takubo, Hiroaki ^a   Komura, Hiroshi ^a   Kogayu, Motohiro ^a   Iwaki, Masahiro ^b  

^a JAPAN TOBACCO INC   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

model based drug development; modeling and simulation; PBPK; pharmacokinetics; renal impairment

Indexed keywords

BATANOPRIDE; CARUMONAM; CEFEPIME; CEFOTETAN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; ENPROFYLLINE; GLUCURONOSYLTRANSFERASE; ISEPAMICIN; LIDOCAINE; MEROPENEM; TOMOPENEM; ZANAMIVIR; DRUG;

AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG ELIMINATION; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HUMAN; INFORMATION PROCESSING; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; LIVER CLEARANCE; PREDICTION; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; COMPLICATION; KIDNEY; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; PATHOPHYSIOLOGY; PHARMACOKINETICS; RENAL INSUFFICIENCY, CHRONIC;

BIOLOGICAL AVAILABILITY; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84908356112     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9626-3     Document Type: Article

References (32)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47. (Pubitemid 350074801)
2. 2013 USRDS annual data report. Available from: www.usrds.org/adr.aspx.
3. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009;86:553-6.
4. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83:898-903. (Pubitemid 351704931)
5. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1-11. (Pubitemid 41740811)
6. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther. 2009;85:305-11.
7. Draft guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling (2010). Available from: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm204959.pdf.
8. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259-67.
9. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008;47:743-52.
10. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189-206.
11. Belpaire FM, Rosseel MT, Vermeulen AM, De Smet F, Bogaert MG. Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure. Mech Ageing Dev. 1993;67:201-10.
12. Mukai H, Morino A. Effects of renal insufficiency and aging on the pharmacokinetics of a phenethylamine class alpha(1A)-adrenoceptor agonist NS-49. Int J Pharm. 1999;185:37-43. (Pubitemid 29333094)
13. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261-74.
14. Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(1 Suppl):91S-108.
15. Strougo A, Yassen A, Krauwinkel W, Danhof M, Freijer J. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. Drug Metab Dispos. 2011;39:1278-87.
16. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos. 2010;38:308-16.
17. Nakamori F, Naritomi Y, Hosoya K, Moriguchi H, Tetsuka K, Furukawa T, et al. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. Drug Metab Dispos. 2012;40:1771-7.
18. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91:129-56. (Pubitemid 34074473)
19. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5. (Pubitemid 23211439)
20. Sayama H, Komura H, Kogayu M, Iwaki M. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics. J Pharm Sci. 2013;102:4193-204.
21. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259-76. (Pubitemid 40904190)
22. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238-57. (Pubitemid 43874439)
23. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065-74.
24. Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta. 1985;151:193-216. (Pubitemid 16238740)
25. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944-58.
26. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326-32. (Pubitemid 32116374)
27. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol. 2002;13:1579-85. (Pubitemid 34579247)
28. Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007;320:978-85. (Pubitemid 46294060)
29. Komura H, Iwaki M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev. 2011;43:476-98.
30. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical signifi cance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34:45-78.
31. Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013;102:2912-23.
32. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10:552-9.